UPDATE: Kindred Biosciences Reports Results from PIVOTAL Study of CereKin in Dogs, Primary Endpoint Was Not Met

By: via Benzinga
Kindred Biosciences, Inc. (KindredBio, NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.